SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS
申请人:Andrews Steven W.
公开号:US20110166122A1
公开(公告)日:2011-07-07
Compounds of Formula (I): in which R
1
, R
2
, R
3
, R
4
, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.
METHOD OF TREATMENT USING SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS
申请人:Andrews Steven W.
公开号:US20130217662A1
公开(公告)日:2013-08-22
Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I
in which R
1
, R
2
, R
3
, R
4
, X, Y and n have the meanings given in the specification.
Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
申请人:Andrews Steven D.
公开号:US08450322B2
公开(公告)日:2013-05-28
Compounds of Formula (I): in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.
Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds
申请人:Array BioPharma, Inc.
公开号:US20160251357A1
公开(公告)日:2016-09-01
Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I
in which R
1
, R
2
, R
3
, R
4
, X, Y and n have the meanings given in the specification.
Method of treatment using substituted imidazo[1,2B]pyridazine compounds
申请人:Andrews Steven W.
公开号:US09227975B2
公开(公告)日:2016-01-05
Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I
in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification.